



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO
09/721,168	11/22/2000	R. Terry Dunlay	97,022-G1	5283
7590 11/03/2004			EXAMINER	
McDonnell Boehnen Hulbert & Berghoff Suite 3200 300 South Wacker Drive Chicago, IL 60606			CHEU, CHANGHWA J	
			ART UNIT	PAPER NUMBER
			1641	
			DATE MAILED: 11/03/2004	i

Please find below and/or attached an Office communication concerning this application or proceeding.

	Application No.	Applicant(s)
	09/721,168	DUNLAY ET AL.
Office Action Summary	Examiner	Art Unit
	Jacob Cheu	1641
The MAILING DATE of this communication app Period for Reply	pears on the cover sheet w	vith the correspondence address
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.1 after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repl - If NO period for reply is specified above, the maximum statutory period of Failure to reply within the set or extended period for reply will, by statute Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	36(a). In no event, however, may a y within the statutory minimum of this will apply and will expire SIX (6) MOI	reply be timely filed rty (30) days will be considered timely. NTHS from the mailing date of this communication.
Status		
1) Responsive to communication(s) filed on 07 Ju	<u>ıly 2004</u> .	
2a) This action is FINAL . 2b)⊠ This	action is non-final.	
3) Since this application is in condition for allowar	nce except for formal mat	ters, prosecution as to the merits is
closed in accordance with the practice under E	x parte Quayle, 1935 C.D). 11, 453 O.G. 213.
Disposition of Claims		
4)⊠ Claim(s) <u>13-15,21-25 and 28-31</u> is/are pending	in the application.	•
4a) Of the above claim(s) is/are withdraw		
5) Claim(s) is/are allowed.		
6)⊠ Claim(s) <u>13-15,21-25 and 28-31</u> is/are rejected		
7) Claim(s) is/are objected to. 8) Claim(s) are subject to restriction and/or		
8) Claim(s) are subject to restriction and/or	election requirement.	
Application Papers		
9)☐ The specification is objected to by the Examiner		
10)☐ The drawing(s) filed on is/are: a)☐ acce	epted or b)⊡ objected to l	by the Examiner.
Applicant may not request that any objection to the o		
Replacement drawing sheet(s) including the correction	on is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
11)☐ The oath or declaration is objected to by the Exa	aminer. Note the attached	Office Action or form PTO-152.
Priority under 35 U.S.C. § 119		
12) Acknowledgment is made of a claim for foreign ∣	priority under 35 U.S.C. §	119(a)-(d) or (f).
a) ☐ All b) ☐ Some * c) ☐ None of:		
1. Certified copies of the priority documents		
2. Certified copies of the priority documents	have been received in Ap	oplication No
 Copies of the certified copies of the priori application from the International Bureau 		received in this National Stage
* See the attached detailed Office action for a list of		received
Attachment(s)	_	
Notice of References Cited (PTO-892) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4) Interview Su	ımmary (PTO-413) /Mail Date
3) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08) Paper No(s)/Mail Date	5) Notice of Inf 6) Other:	ormal Patent Application (PTO-152)

Application/Control Number: 09/721,168

Art Unit: 1641

DETAILED ACTION

Applicant's amendment filed on 7/7/2004 has been received and entered into record and considered.

The following information provided in the amendment affects the instant application:

- 1. Claims 1-12, 16-20, 26-27 are cancelled.
- 2. Currently, claims 13-15,21-25 and 28-31 are under examination.

Claim Rejections - 35 USC § 112

1. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Scope of Enablement

2. Claims 13-15,21-25 and 28-31 are rejected under 35 U.S.C. 112, first paragraph, because the specification, while being enabling for analyzing distribution between nucleus and cytoplasm, does not reasonably provide enablement for cytoplasm and membrane. The specification does not enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to use the invention commensurate in scope with these claims.

The instant invention directs to a method for analyzing distribution of a protein of interest between cell membrane and cell cytoplasm. Applicants disclose using ratio/or difference between the cytoplasm and membrane of a protein of interests as in indication of the cellular distribution of the said protein.

Application/Control Number: 09/721,168

Art Unit: 1641

However, the current invention merely outlines the measuring of intracellular trafficking from cytoplasm to the nucleus which is the also the core content of its parent application, now patented as US 6620591. Particularly, Figures 5, 6, 7, 8, 9, illustrate the measurements of a cell's fluorescent molecules within the local cytoplasmic region of the cell and the translocation of fluorescent molecules from the cytoplasm to the *nucleus* (emphasis added; See page 12, line 21-26). Most importantly, the only two working examples, i.e. example 1 and 2, do not provide any guidance as to the measurement of distribution from cell membrane to the cytoplasm (See example 1 and 2, from page 15-16).

In Example 1, applicant measures the transcription factor by labeling the nuclei, and measuring the nuclei region and cytoplasmic region (See page 15, line 10-25; Figure 6-8). The results are shown in Figure 6 and 8, and applicant clearly indicates the data refer to the cytoplasmic intensity and the nuclear intensity (See page 17, line 1-15). In Example 2, applicant discloses using antibody specific for cell surface marker (myosin and actin) and DNA label Hoechst (See page 18, line 1-15). Note, DNA marker Hoechst is for localization of nuclear proteins trafficking. There is no cytoplasm fluorescent reporter molecule that report on cell membrane is taught in example 2. In light of the instruction outlined in example 2, the set of data acquired in the instant invention merely demonstrate the trafficking between cell surfaces, i.e. membrane, and nuclear, not between cytoplasm and the membrane. Given the fact that both "nuclei" and "cytoplasm" are patentably distinct in terms of the morphology, structures and functions. With limited information, it would be a leap of faith to extrapolate the information from nuclei-cytoplasm to cytoplasm-membrane. Applicant's invention is entitled to encompass analyzing distribution of a protein of interest between cell cytoplasm and the nucleus.

Art Unit: 1641

Response to Applicant's Arguments

- 1. Applicant's arguments with respect to claims 13-15,21-25 and 28-31 have been considered but are most in view of the new ground(s) of rejection.
- 2. Accordingly, the allowable subject matters indicated in the previous Office Action are thus withdrawn pursuant to the new ground of rejections set forth in this Office Action.

Conclusion

3. No claim is allowed.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Jacob Cheu whose telephone number is 571-282-0814. The examiner can normally be reached on 9:00-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Long Le can be reached on 571-272-0823. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

CALIL

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

Jacob Cheu

Examiner

Art Unit 1641

LONG V. LE

SUPERVISORY PATENT EXAMINER
TECHNOLOGY CENTER 1600

10/11/0

October 6, 2004